Aug 2026· Synthetic and Systems Biotechnology· Vol 18, pp. 13 - 24· 0 citations· 60 references
Medicine
TL;DR
A genome-integrated engineered probiotic system enabling gut-local biosynthesis of 5-HTP was developed and results showed that the hTPH2 hydroxylation module, together with the BH4 biosynthesis and regeneration system, supported 5-HTP biosynthesis in EcN.
Abstract
5-Hydroxytryptophan (5-HTP) is a functional precursor of serotonin; however, achieving sustained 5-HTP production in vivo by engineered microbes remains challenging. To address this, we developed a genome-integrated engineered probiotic system enabling gut-local biosynthesis of 5-HTP. Escherichia coli Nissle 1917 (EcN), a clinically validated probiotic with an established safety profile for intestinal application, was selected as the chassis. Constitutive expression was employed to eliminate inducer dependence, while genomic integration was used to enhance genetic stability and avoid reliance on antibiotic selection for pathway maintenance. In addition, BH4 biosynthesis and regeneration modules were incorporated to address the limited endogenous BH4 availability in the gut environment. Different administration strategies were systematically evaluated to characterize in vivo performance. Notably, our results showed that the hTPH2 hydroxylation module, together with the BH4 biosynthesis and regeneration system, supported 5-HTP biosynthesis in EcN. The engineered EcN strain achieved a 5-HTP titer of 863.2 mg/L, the highest level reported in EcN-based systems. Under non-selective conditions, EcNPconst−5−HTP carrying the chromosomally integrated pathway maintained stable 5-HTP production in vitro and retained 5-HTP-producing capacity after intestinal passage, whereas plasmid loss in non-integrated constructs resulted in a pronounced decrease in production. In vivo analysis showed that single-dose administration induced a transient elevation in plasma 5-HTP, whereas repeated dosing generated reproducible, time-dependent fluctuations in fecal bacterial abundance and gut-local biosynthetic activity. Treatment with the engineered probiotic further improved behavioral phenotypes and modulated brain 5-HT-related metabolites in a reserpine-induced mouse model. Together, these findings provide a translational framework linking in vitro 5-HTP production by engineered probiotics to their in vivo functional performance.
This study provides the first demonstration of a 3-HB-producing probiotic yeast and links central metabolic engineering of S. boulardii with increased 3-HB availability, altered SCFA profiles, and a host-relevant epithelial response.
2'-Fucosyllactose (2'-FL), the most abundant human milk oligosaccharide (HMO), has attracted considerable interest for its prebiotic and immunomodulatory functions, with broad applications in infant nutrition. In this study, we report the development of a high-yield, genome-integrated 2'-FL-producing strain based on Es...
Rou-Lin Chen, Longhao Yang, Hao Wang et al.· Enzyme and Microbial Technol...· 0 citations
The results of this study provided a probiotic strain that can synthesize HMB de novo and demonstrated the importance of pantothenic acid availability for EcN metabolic engineering.
J. J. Hung, Tina Wen-Ting Shih, Alice Pin-Yi Du et al.· Journal of Agricultural and...· 0 citations
This review presents a comprehensive analysis of recent advances in microbial BCAAs production through a Mechanism-Module-Process framework, providing a holistic roadmap for constructing superior BCAAs cell factories and extending their metabolic potential toward derivative biosynthesis.
Guihong Zhao, Si-Yu Tian, Jiong-Ran Li et al.· Biotechnology Advances· 0 citations
An Escherichia coli platform for glucose-derived EGT production was developed by combining biosensor-driven evolution and transcriptome-guided chassis engineering, enabling sequential growth-based enrichment and fluorescence-based prioritization.
Su-Yu Wang, H. Zabed, Guoyan Zhang et al.· Journal of Agricultural and...· 0 citations
This study demonstrates a successful paradigm for engineering a newly isolated strain toward robust, high-titer and cost-competitive PHA production across lab-to-industry scales.
Peng Liu, Xinying Xie, Yi-Hao Deng et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.